WHAT CAN WE LEARN FROM NEW MUSCULOSKELETAL EXTENDED SCOPE PRACTITIONER REFERRALS TO RHEUMATOLOGY SECONDARY CARE? A PROSPECTIVE SERVICE EVALUATION

William Dryburgh1, James Bateman2, 1University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom; 2Royal Wolverhampton NHS Trust, Department of Rheumatology, Wolverhampton, United Kingdom

Background: Common non-inflammatory musculoskeletal (MSK) problems are increasingly referred in the UK from primary care to extended scope practitioners (ESPs) that are not doctors. A new local ESP service has been established. Primary care is directed to refer inflammatory problems to secondary care, and non-inflammatory cases to the ESP service, with onward referral to rheumatology if required. There is limited data to show how these services perform, and where they can be improved.

Objectives: The objective is to understand and learn lessons of the patient journey through ESP services, with a view to supporting service design, evaluation, and training needs analysis for ESP and primary care practitioners.

Methods: This is a prospective service evaluation, reviewing patients referred by ESPs to our service seen by a single consultant, over a 42-month period (5/15 –10/18). Patient data was collected prospectively, including age, gender, key clinic-pathologic ESP findings, ESP suspected diagnosis, and the secondary care diagnosis. The ESP suspected diagnosis was recorded. The ESP diagnosis categories, derived from a previous published service evaluation. Our Electronic Patient Record (EPR) was used to check the source data and complete any missing data, and record any secondary care follow up. We excluded any ESP referrals that did not attend, or where missing data could not be found in the EPR.

Results: ESP referrals made up 47/190 (4%) of new patients seen. The average age was 54 (SD 16.9), 38 (81%) were female and 21 (45%) had a history of depression. The main referral concern was ‘small joint inflammatory arthritis’ (20/47, 42%), with 2/20 (10%) confirmed diagnoses requiring follow up (rheumatoid and undifferentiated inflammatory arthritis). The main secondary care diagnosis was osteoarthritis (10/47, 21%), followed by fibromyalgia (9/47, 19%). The majority of the ESP referrals, ultimately had no inflammatory problems with 7/47 (15%) referrals receiving a secondary care diagnosis that was an inflammatory condition. ESPs were most likely to suspect and correctly identify crystal arthritis, correctly suspecting 2/2 cases (100%). They were incorrect for all referrals where they suspected large joint inflammatory arthritis (4), polymyalgia rheumatica (1), axial spondyloarthropathy (4) and connective tissue disease (1). We did find unusual non-inflammatory conditions e.g. a glos- tumour (1). This data was used to design a bespoke ESP training session to 20 ESPs, delivered in December 2018. This included raw data tumour (1). This data was used to design a bespoke ESP training session to 20 ESPs, delivered in December 2018. This included raw data

Disclosure of Interests: None declared


EFFICACY OF ETANERCEPT OVER A PERIOD OF 12 MONTHS IN THE ROUTINE TREATMENT OF PATIENTS WITH RA, AXSJP, Psa OR Pso: FINAL RESULTS OF A GERMAN NON-INTERVENTIONAL, PROSPECTIVE, MULTI-CENTER STUDY (ADEQUATE)

Eugen Feist1, Xenofon Baraliakos2, Frank Behrens3, Diamant Thaçi4, William Dryburgh1, James Bateman2. 1374 Saturday, 15 June 2019

Disclosure of Interests: Eugen Feist Grant/research support from: Pfizer, Roche, Novartis, BMS, Sanofi, Lilly, Consultant for: Pfizer, Roche, Novaris, BMS, AbbVie, Celgene, Sanofi, MSD, Lilly, Speakers bureau: Pfizer, Roche, Novartis, BMS, AbbVie, Celgene, Sanofi, Lilly, Xenonon Baraliakos Grant/research support from: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Chugai, Janssen, MSD, Novartis, Pfizer Inc, Roche and UCB, Grant/research support from: AbbVie, Pfizer, Merck Sharp & Dohme, UCB Pharma, Novartis, Consultant for: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Janssen Biologics, Novartis, Pfizer, UCB Pharma, Galapagos, Speakers bureau: AbbVie, Chugai, Janssen, Novartis, Pfizer, UCB Pharma, Frank Behrens Grant/ research support from: Pfizer, Janssen, Novartis, Roche, Consultant for: AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly, Sanofi, Sandost, Boehringer, Speakers bureau: AbbVie, Pfizer, Roche, Chugai, UCB, BMS, MSD, Celgene, Novartis, Biotest, Janssen, Genzyme, Lilly, sanofi, Sandost, Boehringer, Diamant Thaçi Grant/research support from: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Chugai, Janssen, MSD, Novartis, Pfizer Inc, Roche and UCB, Grant/research support from: AbbVie, Pfizer, Merck Sharp & Dohme, UCB Pharma, Novartis, Consultant for: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, DERMIRA, ECI, Lilly, Forward Pharma, GlaxoSmithKline, Janssen Cilag, Leo Pharma, Novartis, Pfizer, Regeneron, Roche, Sandost-Hexal, Sanofi, and UCB, Consultant for: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, DERMIRA, Galapagos, Leo Pharma, Lilly, Novaris, Pfizer, and Janssen Biologics, AbbVie, Bristol-Myers Squibb, Celgene, DERMIRA, GlaxoSmithKline, Janssen Cilag, Leo Pharma, Morphosis, Novartis, Pfizer, Sando, Sanofi, and UCB, Thilo Klopsch Shareholder of: AbbVie, Amgen, Astellas Pharma, Celgene, Genzyme, Lilly, Novartis, Boehringer Ingelheim, Janssen Biologics, Johnson & Johnson, Anja Plassek Employee of: Pfizer Pharma GmbH, Lisa Kristina Blindzeliner Employee of: Pfizer Pharma GmbH, Thomas

Background: For patients with chronic autoimmune diseases such as rheumatoid arthritis (RA), axial spondyloarthritides (axSpA), psoriatic arthritis (PsA) or plaque psoriasis (PsO), the treat-to-target concept requires...